Inactive Instrument
Provectus Biopharmaceuticals Inc Share Price NYSE
Stocks
US74373P1084
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 19/06 | Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call | |
| 18/05 | Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study | RE |
| Market Cap | 2.87Cr 2.53Cr 2.33Cr 2.18Cr 4.09Cr 270.81Cr 4.16Cr 28Cr 11Cr 133.59Cr 11Cr 11Cr 464.78Cr | P/E 2024 |
-10.6x | P/E 2025 | -4.33x |
|---|---|---|---|---|---|
| Enterprise Value | 3.15Cr 2.77Cr 2.55Cr 2.39Cr 4.48Cr 296.52Cr 4.56Cr 31Cr 12Cr 146.27Cr 12Cr 12Cr 508.9Cr | EV / Sales 2024 |
8,64,51,912x | EV / Sales 2025 | 7,80,13,766x |
| Free-Float |
92.21% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Provectus Biopharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 73 | 16/04/2024 |
Eric Wachter
CTO | Chief Tech/Sci/R&D Officer | 62 | 15/05/2012 |
Heather Raines
DFI | Director of Finance/CFO | 59 | 25/03/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 57 | 03/04/2017 | |
John Lacey
BRD | Director/Board Member | 78 | 27/04/2018 |
Edward Pershing
CHM | Chairman | 73 | 27/04/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.29% | -1.63% | +55.33% | +109.61% | 5.29TCr | |
| +8.55% | +17.52% | +72.65% | +82.31% | 5.1TCr | |
| -0.45% | -2.18% | -14.16% | -15.80% | 2.28TCr | |
| +1.28% | +5.09% | -2.30% | +418.34% | 2.24TCr | |
| +2.03% | +7.40% | +28.79% | -13.91% | 1.7TCr | |
| -0.69% | +4.12% | +28.77% | -34.82% | 1.59TCr | |
| +2.98% | +0.82% | +15.64% | +166.21% | 1.33TCr | |
| +5.94% | +14.85% | +134.05% | +296.09% | 1.36TCr | |
| -0.71% | +1.98% | +78.88% | +114.48% | 1.18TCr | |
| Average | +2.13% | +5.20% | +44.18% | +124.72% | 2.45TCr | |
| Weighted average by Cap. | +2.73% | +5.40% | +46.04% | +116.92% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0.62 0.54 0.5 0.47 0.88 58.17 0.89 6.02 2.33 28.7 2.32 2.27 99.84 | 0.34 0.3 0.27 0.26 0.48 31.68 0.49 3.28 1.27 15.63 1.26 1.23 54.37 |
| Net income | -47.62L -41.93L -38.67L -36.17L -67.77L -45Cr -69.03L -4.65Cr -1.8Cr -22Cr -1.79Cr -1.75Cr -77Cr | -54.31L -47.81L -44.1L -41.25L -77.28L -51Cr -78.73L -5.3Cr -2.05Cr -25Cr -2.04Cr -1.99Cr -88Cr |
| Net Debt | 28.77L 25.33L 23.37L 21.85L 40.95L 27Cr 41.71L 2.81Cr 1.09Cr 13Cr 1.08Cr 1.06Cr 47Cr | 27.27L 24.01L 22.15L 20.71L 38.81L 26Cr 39.54L 2.66Cr 1.03Cr 13Cr 1.02Cr 1Cr 44Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
